Advertisement

Topics

Savara Inc. Company Profile

23:57 EDT 22nd May 2019 | BioPortfolio

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3-stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2-ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/)


News Articles [21 Associated News Articles listed on BioPortfolio]

Savara Inc.: Savara to Present at the H.C. Wainwright Global Life Sciences Conference in London

AUSTIN, TX / ACCESSWIRE / April 2, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that Rob Neville, Chief Executive Officer, will present at the H.C. Wainwright ...

Savara Inc.: Savara to Present at the 39th Annual Cowen and Company Healthcare Conference

AUSTIN, TX / ACCESSWIRE / March 4, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, announced today that the company's Chief Executive Officer, Rob Neville, will present at the 39...

Savara Inc.: Savara Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update

On-Track to Report Top Line Results from Pivotal Phase 3 IMPALA Study at End of Q2 2019 AUSTIN, TX / ACCESSWIRE / March 13, 2018 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today ...

Savara Inc.: Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection in People Living with Cystic Fibrosis

AUSTIN, TX / ACCESSWIRE / April 1, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced the initiation of ENCORE, a Phase 2a clinical study evaluating its lead product...

FDA fast-tracks Savara's lung disease therapy

Savara's Molgradex, or molgramostim, has been granted fast-track designation by the FDA.  -More- 

Savara completes enrolment for Phase IIa Molgradex trial

Savara has completed patient enrolment in the Phase IIa OPTIMA clinical trial to examine molgradex for the treatment of nontuberculous...Read More... The post Savara completes enrolment for Phase IIa ...

Savara to Present at the H.C. Wainwright Global Life Sciences Conference in London

AUSTIN, TX / ACCESSWIRE / April 2, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that Rob Neville, Chief Executive Officer, will present at the H.C. Wainwright Gl...

Savara to Report First Quarter 2019 Financial Results and Provide Business Update

Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report first quarter 2019 financial results and provide a business update ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Savara Inc.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development f...

Savara, Inc.

Savara Pharmaceuticals

More Information about "Savara Inc." on BioPortfolio

We have published hundreds of Savara Inc. news stories on BioPortfolio along with dozens of Savara Inc. Clinical Trials and PubMed Articles about Savara Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Savara Inc. Companies in our database. You can also find out about relevant Savara Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record